Role of Alprazolam in the Management of Acute Coronary Syndrome

  • STATUS
    Recruiting
  • End date
    Feb 20, 2022
  • participants needed
    48
  • sponsor
    Sohaib Ashraf
Updated on 3 February 2021

Summary

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

Description

World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to chest pain and hospital admission causing tachycardia. This study is designed to achieve the goals of lowering the heart using the anxiolytic property of alprazolam. This randomized, parallel group, close label, placebo-controlled, event driven, interventional clinical superiority study will be conducted in Cardiology department of Shaikh Zayed Hospital with a sample size of 48 allocating using lottery method in both experimental and control group. Heart Rate at baseline and after 6 hours will be monitored in both groups to establish the fall of heart rate in both patients. Data will be collected by using pre-designed performa and will be entered and analyzed via SAS 9.4. Statistical analysis will be done using T-test and p value <0.05 will be considered significant.

Significance of the study is to lower the required dosage of beta-blockers in order to achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.

Details
Condition Heart disease, Myocardial Infarction, Acute Coronary Syndrome, Cardiovascular Disease, ANXIETY NEUROSIS, Anxiety, Ischemic Heart Disease, Anxiety Disorders (Pediatric), Generalized Anxiety Disorder (GAD), Heart Attack (Myocardial Infarction), STEMI, ST Elevation Myocardial Infarction, Generalized Anxiety Disorder (GAD - Pediatric), Anxiety Symptoms, Anxiety Disorders, Cardiac Ischemia, Myocardial Ischemia, Cardiac Disease, heart attack, myocardial infarction (mi), cardiac infarction, heart attacks, myocardial necrosis, cardiac diseases, heart diseases, cardiac disorders, cardiac disorder, heart disorder, acute coronary syndromes, anxiety disorder, anxious
Treatment Placebo, Alprazolam
Clinical Study IdentifierNCT04715269
SponsorSohaib Ashraf
Last Modified on3 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Systolic BP>100mm Hg Age between 18-80 years Sinus Rhythm

Exclusion Criteria

Cardiogenic Shock / Hypotension
Known Asthma/COPD
Bradycardia (HR < 60)
Already on Beta blockers/ Anxiolytics
Sick sinus syndrome
Second or third-degree heart block (in the absence of pacemaker)
Decompensated heart failure
With documented hypersensitivity to the drug or components
Valvular Heart Diseases
Congenital Heart Diseases
Status post CABG
Any co-morbidities except Diabetes Mellitus and Hypertension
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note